Overview

Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Status:
Recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)

Phase:

Phase 1

Details

Lead Sponsor:

Stanford University

Collaborators:

Breast Cancer Research Foundation
National Cancer Institute (NCI)
QED Therapeutics, Inc.

Treatments:

Fulvestrant
Infigratinib
Palbociclib
Tamoxifen